secwatch.observer — SEC 8-K summary
======================================

Issuer:     Wave Life Sciences Ltd. (WVE)
CIK:        0001631574
Form:       8-K
Filed at:   2024-10-15T23:59:59+00:00
Accession:  0001193125-24-237665
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Takeda terminates HTT option; Wave Life Sciences regains full rights to WVE-003 Huntington's program
--------------------------------------------------------------------------------

- Takeda notified Wave it will not exercise option for HTT target, ending collaboration; Takeda previously paid ~$260M to Wave.
- Wave regains full rights to WVE-003 and all HTT-targeting programs, with potential $5B-$10B commercial opportunity.
- SELECT-HD clinical trial data generated significant interest from prospective partners for WVE-003.
- Wave expects regulatory feedback on accelerated approval pathway for WVE-003 by end of 2024.
- Cash runway unchanged into 2027, excluding potential GSK milestones.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1631574/000119312524237665/0001193125-24-237665-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1631574/000119312524237665/d899308d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-237665

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer